Showing posts with label AP. Show all posts
Showing posts with label AP. Show all posts

Tuesday, June 23, 2020

Verdicts of three California juries nixed

Federal judge sides with Monsanto, blocks cancer-warning labels from most widely used weed-killer


Ignoring the verdicts of three California juries, a federal judge ruled yesterday that the state can’t require a warning label on Roundup.

U.S. District Judge William Shubb
U.S. District Judge William Shubb, according to an Associated Press story, issued a permanent injunction against the labeling of the world’s most widely used weed-killer — despite plaintiffs in the three cases having won nearly $300 million after the juries agreed that glyphosate, the main ingredient in Roundup, Monsanto’s herbicide, causes non-Hodgkin’s lymphoma and other blood cancers.

The AP cited a contrary quote by Shubb in the San Francisco Chronicle to the effect that “the great weight of evidence indicates that glyphosate is not known to cause cancer.”

The U.S. District judge noted that the U.S. Environmental Protection Agency and similar agencies in Europe “haven’t found a connection between the chemical and cancer.”

The judge contended, according to the AP, that “the state couldn’t meet a legal standard” for requiring the labeling — in effect overturning California’s warning requisite on cancer-causing products under its Safe Drinking Water and Toxic Enforcement Act that was approved in 1986 by voters. 

California had wanted the labels based on a 2016 finding by the International Agency for Research on Cancer, an arm of the World Health Organization, that glyphosate "was probably a cause of cancer in humans.”

Monsanto, which is now owned by Bayer AG, a German chemical and pharmaceutical giant, sued to overturn that position and, in 2018, Shubb temporarily blocked the labeling. In his latest ruling, the judge suggested that the state can force a company to change its label only if the statement is purely factual and non-controversial — itself apparently a controversial posture.

The monster agribusiness, meanwhile, has appealed the verdicts in all three cases.

It had been facing some 125,000 lawsuits in spite of contending Roundup is safe. But of those cases — reports a story on the EcoWatch website that features “environmental news for a healthier planet and life” — Bayer “made a verbal agreement to settle 50,000 to 85,000 cases in May, awarding plaintiffs anywhere from a few thousand dollars to a few million, according to Fortune” magazine.

The reason for those settlements, EcoWatch speculated, is “the spate of lawsuits and their legal fees [that] made the company lose 40 percent of its value.”

Lawyers for the plaintiffs in those instances, that article continues, “argued that the EPA’s insistence that Roundup does not cause cancer is spurious since there was evidence the company had unduly influenced the federal agency and had ‘ghost-written’ purported research studies on the product’s safety.” 

The story also noted that the verdicts in the three cases with huge settlements, all of which are being appealed by Monsanto, came after the plaintiffs alleged that “Bayer manipulated studies and deceived the scientific community to make glyphosate seem safer than it actually is, according to Reuters.”

More information about lawsuits pertaining to products that may cause disease can be found in “Rollercoaster: How a man can survive his partner’s breast cancer,” a VitalityPress book that I, Woody Weingarten, aimed at male caregivers.

Friday, April 17, 2020

2 experimental drugs might extend patients' lives

Renewed hope is possible for women with aggressive breast cancer, new study indicates


Two experimental drugs might help women with an aggressive form of breast cancer, results of a new study show.

According to a recent Associated Press story by Marilynn Marchione that cites reports in the New England Journal of Medicine and at a San Antonio Breast Cancer Symposium that the cancers "had spread widely and and resisted many previous treatments," one drug "showed particular ability to reach tumors in the brain, which are notoriously tough to treat."

The other combines "a sort of homing device for cancer cells with a payload of chemotherapy that's released when it reaches its target."


Dr. Ian Krop in his office.
Marchione's article quotes the study's leader, Dr. Ian Krop of the Dana-Farber Cancer Institute in Boston, to the effect that infusions of T-DXd, the second drug, become "a guided missile…able to bring the chemotherapy directly to the cancer cell."

That study — focusing on often-fatal HER2-positive cancers, which have a protein on their cell surfaces driven by an overactive gene that promotes tumor growth — tested TDXd on 253 women

Most of the them, who had, on average, tried six other treatments before the experimental drug, saw their tumors shrink — and 6 percent of them found zero signs of cancer in at least two followup scans.

The positive response rate, the AP story again quotes Krop, "is three to four times better than what's usually seen in this situation." 

To see results showing a median time of 16 months until cancer worsened "is exciting," he added.

All involved, however, noted that side effects — including lung inflammation, low blood counts, nausea, anemia or fatigue — were substantial.

But anti-inflammatory meds can alleviate some of those issues, it's believed.

The study was sponsored by the drug's developers, Daiichi Sankyo Inc. and AstraZeneca, who are seeking approval in the United States, Europe and Japan.

Study of the other drug — tucatinib, from Seattle Genetics — was done on 612 patients. Its side effects included diarrhea, fatigue, nausea and some liver issues, but 45 percent of those on the drug were alive two years after being given it (along with the usual treatments, Herceptin and the chemo drug Xeloda) as opposed to 27 percent who weren't.

More information on experimental drugs can be found in "Rollercoaster: How a man can survive his partner's breast cancer," a VitalityPress book that I, Woody Weingarten, aimed at male caregivers.

Friday, July 13, 2018

400 lawsuits filed against Monsanto's herbicide

Is Monsanto's Roundup weed killer carcinogenic? Contentious trial underway in San Francisco  

The first court trial to determine if Roundup weed killer is likely to cause cancer is underway in San Francisco.

According to an Associated Press story by Sudhin Thanawala , the contentious trial — with a school groundskeeper dying of the disease as the plaintiff and agribusiness giant Monsanto, the hericide's manufacturer, as defendant — is expected to last about a month.
Dewayne Johnson, plaintiff
The plaintiff, Dewayne Johnson, who was diagnosed in 2014 at age 42, claims Roundup caused his non-Hodgkin's lymphoma after he sprayed it from a 50-gallon tank attached to a truck as a school district pest control manager. 

The AP quoted the opening statement of Johnson's attorney, Brent Wisner, to the effect that "when the wind was gusty, it would cover his face. When a hose broke once, it soaked his entire body."

The attorney showed jurors photographs of lesions on the body of the plaintiff, who had also sprayed with a similar product, Ranger Pro. 

Wisner alleged that between the diagnosis "and now, it's just nothing but pain."

Monsanto's lawyer, George Lombardi, countered by saying that "non-Hodgkin's lymphoma takes years to develop, so Johnson's cancer started well before he began working at the school district."

Thanawala's story notes that "many government regulators have rejected a link between the active ingredient in Roundup — glyphosate — and cancer. Monsanto has vehemently denied such a connection, saying hundreds of studies have established that glyphosate is safe."

While the plaintiff "is seeking unspecified damages against Monsanto [and] the outcome of Johnson's case will not affect the hundreds of other lawsuits in state and federal courts...it may serve as an indicator of how the others might go."

Earlier this week, a San Francisco U.S. District judge, Vince Chhabria, ruled that although evidence seems weak that Roundup causes cancer, experts still could make that claim at trial.

The main claim of the lawsuits by cancer victims and their families is that Monsanto long knew about Roundup's cancer risk but failed to warn them.

Chhabria is handling more than 400 of those suits.

The AP article indicates that Monsanto developed glyphosate in the '70s and that the weed killer is sold in more than 160 countries. "Farmers in California, the most agriculturally productive state in the U.S., use it on more than 200 types of crops. Homeowners use it on their lawns and gardens."

In 2015, the France-based International Agency for Research on Cancer, part of the World Health Organization, classified the herbicide as a "probable human carcinogen." California later added it to its list of chemicals known to cause cancer.

But the U.S. Environmental Protection Agency, according to the AP, "says glyphosate is safe for humans when used in accordance with label directions."

And in February, the story continues, a federal judge in Sacramento blocked California from required that Roundup carry a warning label, saying it would be "misleading because almost all regulators have concluded that there is no evidence glyphosate is carcinogenic."

In Johnson's case, according to an online story by Helen Christopher of Courthouse News Service, San Francisco County Superior Court Judge Suzanne Ramos Bolanos sided with Monsanto yesterday by disallowing testimony of an cancer-risk expert. The ruling came on a technicality after the corporation's lawyers accused the plaintiff's legal team of trying to sneak into evidence information about the amount of exposure Johnson experienced.

Much more information about cancer causes can be found in "Rollercoaster: How a man can survive his partner's breast cancer," a VitalityPress book I, Woody Weingarten, aimed at male caregivers.

Tuesday, January 19, 2016

Are researchers, discoveries being cloistered?

Biden urges end to 'cancer politics' but more teamwork among docs, scientists, donors



Vice President Joseph Biden

It's a presidential election year so, naturally, there's lots of disturbing politics (no matter where you're positioned on the bell curve).

Perhaps none more upsetting, however, than the politics of the cancer world that, according to Vice President Joseph Biden, is the greatest obstacle to curing the disease.

According to a recent Associated Press story by Josh Lederman, Biden — who lost his 46-year-old son, Beau, to brain cancer last May — is now asking Americans to demand that scientists collaborate to overcome "cancer politics" and, thereby, find a cure.

His rallying cry came a month after he announced he wouldn't run for president.

Biden delivered his plea in Houston at the MD Anderson Cancer Center, whose Moon Shots program is aimed at finding an end to the massive killer.

The story says the vice president's found, after meeting with almost 200 oncologists, scientists and benefactors in the cancer community, an excess of "competition, territorialism and resistance to information-sharing."

The result, they apparently indicated to him, is that "researchers and their discoveries [have been left] cloistered in their own corners."

Biden plans not only to seek more funding but to encourage increased data-sharing.

It's been half a century since President Nixon declared war on cancer. Clearly, the war has not been won (despite survival rates having been improved, the American Cancer Society has predicted, according to the AP story, "1.7 million new cancer cases this year and nearly 600,000 deaths").

In a follow-up to his initial announcement, Biden softened his personal "moon shot" from facilitating a cure to a more realistic goal of doubling the rate of progress (meaning researchers would accomplish in five years what normally would take 10).

It's been unclear, however, exactly what "cure" Biden seeks — considering that cancer is hardly monolithic.

To learn more about that, and how researchers keep changing their minds and findings, check out "Rollercoaster: How a man can survive his partner's breast cancer," a book I, Woody Weingarten, aimed especially at male caregivers.